PIR International was delighted to partner with Gilgamesh Pharmaceuticals on the appointment of Bridget Walton as VP Regulatory Affairs.
Gilgamesh Pharmaceuticals is a clinical-stage neuroscience biotech developing innovative, best-in-class new chemical entities (NCEs) that transform the treatment paradigm of psychiatric diseases, moving away from symptom management towards rapid-acting and durable therapies.
Following a comprehensive, US-centric search led by PIR International, Gilgamesh Pharmaceuticals successfully appointed Bridget Walton, MS, RAC (DRSc cand.) into this pivotal leadership role. The appointment represents a critical addition to Gilgamesh’s executive team, bringing high-impact regulatory expertise at a time of significant momentum for the business. With strong visibility internally and across the broader industry, the role is positioned to play a meaningful part in shaping Gilgamesh’s future success and accelerating the delivery of transformational psychiatric therapies to patients.
Jorge Quiroz, MD MBA, Chief Strategy & Development Officer of Gilgamesh Pharmaceuticals, said: “As Gilgamesh enters its next phase of growth, strengthening our regulatory leadership was a strategic priority. Bridget brings the experience, judgment, and executional rigor required to guide multiple programs through global regulatory interactions and position the company for long-term success. Thank you to Tom and Stuart for steering a highly collaborative, professional and efficient process.”
Bridget Walton, VP Regulatory Affairs at Gilgamesh Pharmaceuticals, commented: “I am excited to join Gilgamesh at such a pivotal time. The company’s differentiated science and commitment to transforming psychiatric care present a unique opportunity to build thoughtful, forward-looking regulatory strategies that can efficiently advance these promising therapies to patients.”